Credit: Shutterstock photoTimothy Ring ( Insider Trades ), CEO and Chairman of C.R. Bard Inc. ( BCR ), sold 9-,-9' shares of the company on Sept. -8, -…-6. The average price per share was $--7.8-, for a total transaction of $--,…-5,-68. C.R. Bard, a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in vascular, urology, oncology and surgical specialty products, has a market cap of $-6.47 billion.
Including the aforementioned transaction, Ring sold a total of -,…--,-'7 shares of the company in 5- transactions since the beginning of -…-'. Ring's earliest insider sell of -…,-6- shares at an average price of $99.88 per share has increased in value by about --4% since the date of transaction. The total volume of insider shares sold per year decreased each year since -…-'. There were 67 BCR insider sells totaling -,-79,8'- shares in -…-', and 5' insider sells totaling 74',-57 shares in the following year. The number of insider sells increased to 56 in -…-5. However, the total number of insider shares sold decreased to 57-,454. Ring contributed to -…-,-9' shares of the '75,77- total insider shares sold in -…-6 to date. For more information about insider trades with BCR, click here .
- David Einhorn Undervalued Stocks
- David Einhorn Top Growth Companies
- David Einhorn High Yield stocks
- Jim Simons Undervalued Stocks
- Jim Simons Top Growth Companies
- Jim Simons High Yield stocks
The company reported net sales of $9'-.5 million in the second quarter ended June '…, -…-6. Net sales income is up from $859.8 million reported in the previous year's second quarter. Net loss also increased from $54.7 million, or 74 cents per share, to $-59.- net income of million, or $-.-4 per share, when comparing the same periods of time.
Ring commented that the company sees "strong results as [they] prioritize product leadership across the globe." The company announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption ( IDE ) supplemental application to modify the primary endpoint to a six-month time point for the Lutonix …-4 Drug Coated Balloon PTA Catheter (DCB). The Lutonix is currently the only DCB in an IDE clinical trial in the U.S. for treatment of arteries below the knee. The clinical trial is evaluating the use of the device as treatment of stenosis or occlusion of native below the knee arteries with a cumulative lesion length up to '-… mm with reference vessel diameters of - mm to 4 mm.
According to GuruFocus.com information, C.R. Bard Inc. has a business predictability rank of - out of 5 stars. For more information about business predictability rank, click here .
Paul Tudor Jones (Trades, Portfolio) and Jim Simons (Trades, Portfolio) both reduced their stake in BCR during the second quarter of -…-6. Jones decreased his stake by 99.5-%, selling --4,8…… shares at an average per share price of $--7.--. Jones increased his stake by 86.97% and 45.76% at an average per share price of $-87.'- and $-88.7- in the fourth quarter of -…-5 and first quarter of -…-6, respectively. The total estimated gain of the holding since the fourth quarter of -…-' is about -7%. Simons reduced his stake in BCR by --.55%, selling -9-,-…… shares of the company after previously increasing his stake in BCR by -'.'8%. The total estimated gain of the holding since the first quarter of -…-- is about '-%. For more information about guru trades with BCR, click here.
For more stock trades of gurus in real time, visit GuruFocus'Real Time Picks , a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here .
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
